诺和诺德称减肥药Wegovy®口服片剂已在美国获批

Core Viewpoint - Novo Nordisk's Wegovy oral tablet has received approval in the United States, marking it as the first oral GLP-1 medication for weight management. The company plans to launch the product in January 2026 [1]. Group 1 - Wegovy oral tablet demonstrates weight loss effects comparable to the Wegovy 2.4 mg injection [1]. - In the OASIS 4 trial, one in three participants experienced a weight loss of 20% or more [1].